Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06018883 | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer(PTCA199-3) | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06319755 | Characteristics of Intestinal Microbiome Following Pancreatic Surgery | unknown | — | 20 | Royal Prince Alfred Hospital, Sydney, AustraliaOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06873178 | The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer(PCLM:CSSG) | unknown | — | 50 | China-Japan Friendship HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | unknown | Phase 1 / Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05504265 | Perioperative Analgesia Modes in Minimally Invasive Esophagectomy | unknown | Phase 2 / Phase 3 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06438705 | 99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors | unknown | — | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 | clinicaltrials |
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study(INSPIRE) | unknown | — | 5,350 | Singlera Genomics Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06562140 | Multidimensional Examination of Patients with Colorectal and Anal Cancer(MECACP) | unknown | — | 300 | University of PecsOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06773260 | Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC(ELASTO-HCC) | unknown | — | 150 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06216743 | PRE- MISTIC: MRI and Cine Imaging to Improve Staging of Tumors in the Colon(PRE-MISTIC) | unknown | N/A | 15 | Radboud University Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06736678 | Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients | unknown | N/A | 98 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05215665 | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma | unknown | N/A | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05980403 | Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237） | unknown | — | 300 | Yongshun ChenOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT06646809 | Reducing Inflammatory Syndrome in Surgery - Colorectal (RISIS-CR) Trial(RISIS-CR) | unknown | Phase 3 | 80 | National University Hospital, SingaporeOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04675138 | Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care | unknown | — | 1,000 | National University Hospital, SingaporeOTHER | 6 | Oct 10, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | unknown | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06607120 | Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies | unknown | — | 950 | Zhongda HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06210724 | FIT in Diverticulitis | unknown | — | 275 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06587152 | Clinical Trial to Evaluate the Efficacy and Safety of a Thoracic and Abdominal Endoscopic Surgical System | unknown | N/A | 60 | Cornerstone RoboticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06590844 | "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06590948 | Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS | unknown | — | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05991947 | Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer | unknown | — | 1,100 | Zhejiang Cancer HospitalOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06577272 | Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients | unknown | — | 6,000 | Tian'an JiangOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06578858 | Immunonutrition and Psychosocial Factors in the Recovery of Patients After Gastrectomy: a Multidimensional Analysis | unknown | — | 40 | Universidade Federal de PernambucoOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT05381792 | Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia(M3-CAN) | unknown | — | 50 | Chinese University of Hong KongOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06486545 | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | unknown | N/A | 18 | Hunan Cancer HospitalOTHER | 0 | Aug 26, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06571396 | Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma | unknown | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03256201 | Exercise and Nutrition to Improve Pancreatic Cancer Outcomes | unknown | N/A | 95 | University of OklahomaOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05385250 | Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II(DACG-II) | unknown | N/A | 100 | Karen-Lise Garm SpindlerOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06475170 | Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy | unknown | N/A | 60 | Northern Jiangsu People's HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06540027 | The Effect of Minimally Invasive Surgery on Systemic Inflammatory Response in Rectal Cancer | unknown | — | 80 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05570279 | PLAN-A Data- Bio- and Plan- Bank Collection for SCCA in Denmark(PLAN-A) | unknown | — | 314 | Aarhus University HospitalOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06550063 | HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes(HERA) | unknown | — | 2,188 | St. James's Hospital, IrelandOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06248580 | Find HDV and Determine Its Status in Turkey(SITUHDVATION) | unknown | — | 20,000 | Yaşar Bayındır, MDOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2025source: clinicaltrials